|
Q2 FY2025
As of Mar 31, 2025
|
Q1 FY2025
As of Dec 31, 2024
|
Q4 FY2024
As of Sep 30, 2024
|
Q3 FY2024
As of Jun 30, 2024
|
Q2 FY2024
As of Mar 31, 2024
|
Q1 FY2024
As of Dec 31, 2023
|
Q4 FY2023
As of Sep 30, 2023
|
Q3 FY2023
As of Jun 30, 2023
|
Q2 FY2023
As of Mar 31, 2023
|
Q1 FY2023
As of Dec 31, 2022
|
Q4 FY2022
As of Sep 30, 2022
|
Q3 FY2022
As of Jun 30, 2022
|
Q2 FY2022
As of Mar 31, 2022
|
Q1 FY2022
As of Dec 31, 2021
|
Q4 FY2021
As of Sep 30, 2021
|
Q3 FY2021
As of Jun 30, 2021
|
Q2 FY2021
As of Mar 31, 2021
|
Q1 FY2021
As of Dec 31, 2020
|
Q4 FY2020
As of Sep 30, 2020
|
Q3 FY2020
As of Jun 30, 2020
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Interest-bearing deposits with other institutions | ||||||||||||||||||||
| Total cash and cash equivalents | ||||||||||||||||||||
| Investment securities available for sale, at fair value (net of allowance for credit losses of $0) | ||||||||||||||||||||
| Investment securities held to maturity, at amortized cost (net of allowance for credit losses of $0) | ||||||||||||||||||||
| Loans held for sale | ||||||||||||||||||||
| Loans receivable (net of allowance for credit losses of $15,416 and $18,525) | ||||||||||||||||||||
| Loans receivable (net of allowance for credit losses of $14,950 and $15,306) | ||||||||||||||||||||
| Regulatory stock, at cost | ||||||||||||||||||||
| Premises and equipment, net | ||||||||||||||||||||
| Bank-owned life insurance | ||||||||||||||||||||
| Foreclosed real estate | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Deferred income taxes | ||||||||||||||||||||
| Derivative and hedging assets | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| LIABILITIES | ||||||||||||||||||||
| Deposits | ||||||||||||||||||||
| Short-term borrowings | ||||||||||||||||||||
| Other borrowings | ||||||||||||||||||||
| Advances by borrowers for taxes and insurance | ||||||||||||||||||||
| Derivative and hedging liabilities | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| TOTAL LIABILITIES | ||||||||||||||||||||
| STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
| Common stock ($0.01 par value; 40,000,000 shares authorized, 18,133,095 issued; 10,154,664 and 10,123,708 outstanding at March 31, 2025 and September 30, 2024, respectively) | ||||||||||||||||||||
| Additional paid in capital | ||||||||||||||||||||
| Unallocated common stock held by the Employee Stock Ownership Plan (ESOP) | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Treasury stock, at cost; 7,978,431 and 8,009,387 shares outstanding at March 31, 2025 and September 30, 2024, respectively | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| TOTAL STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY |
Loading...
